

Appendix A

Claim Amendments

1. (Currently amended) Pharmaceutical A pharmaceutical
suspension formulation comprising
 - a. particles of formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
 - b. particles of ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation and
 - c. a propellant selected from the group consisting of
1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof.
2. (Currently amended) Pharmaceutical The pharmaceutical
suspension formulation according to claim 1 consisting of comprising
 - a. particles of micronized formoterol, or a pharmaceutically acceptable salt, solvate or

physiologically functional derivative thereof, said particles being suspended in the formulation,

- b. particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,
- c. ethanol,
- d. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and
- e. optionally a surfactant.

3. (Currently amended) Suspension The pharmaceutical suspension formulation according to claim 1 any of the preceding claims containing less than 3% by weight of ethanol.

4. (Currently amended) Pharmaceutical The pharmaceutical suspension formulation according to claim 1 consisting of comprising

- a. particles of micronized formoterol, or a pharmaceutically acceptable salt, solvate or

physiologically functional derivative thereof, said particles being suspended in the formulation,

b. particles of micronized ciclesonide or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation,

c. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and

d. a surfactant.

5. (Currently amended) Suspension The pharmaceutical suspension formulation according to claim 1 which comprises any of the proceeding claims containing R,R-formoterol.

6. (Currently amended) Suspension The pharmaceutical suspension formulation according to claim 1 which comprises any of the proceeding claims containing formoterol fumarate dihydrate.

7. (Currently amended) Suspension The pharmaceutical suspension formulation according to claim 1 which

~~comprises any of the proceeding claims containing oleic acid as surfactant.~~

8. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1 which ~~comprises any of the proceeding claims containing~~ about 0.001 to 0. 1 % (w/w) of oleic acid.
9. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1 which ~~comprises any of the proceeding claims containing~~ HFA 227 as propellant.
10. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1 comprising containing disodium chromoglycate at a concentration which is concentrations, which are not therapeutically and/or prophylactically active.
11. (Currently amended) ~~Suspension~~ The pharmaceutical suspension formulation according to claim 1, which is administered in a once daily dosing regimen.